Recent Quotes
My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cel-Sci Corporation Common Stock (NY:CVM)

1.980 -0.080 (-3.88%)
Streaming Delayed Price Updated: 10:32 AM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cel-Sci Corporation Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
What's Going On With Cel-Sci Shares Premarket On Monday? ↗
Cel-Sci announces public offering of 16.13M shares at $0.31 per share, aiming to raise $5M for Multikine development and general purposes. 
Via Benzinga
News headline image
US Stock Futures Slip After Friday's Fall: 'Santa Rally' In Doubt? Analyst Calls It A Bit Of Profit-Taking ↗
U.S. stock futures declined on Monday after ending lower on Friday. All four index futures slipped in trade. 
Via Benzinga
News headline image
Why Vincerx Pharma Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
CCSC Technology International, CEL-SCI And 3 Stocks To Watch Heading Into Monday ↗
 
Via Benzinga
News headline image
CVM Stock Earnings: CEL-SCI Misses EPS for Q3 2024 ↗
CVM stock results show that CEL-SCI missed analyst estimates for earnings per share the third quarter of 2024. 
Via InvestorPlace
News headline image
CVM Stock Earnings: CEL-SCI Reported Results for Q2 2024 ↗
CEL-SCI just reported results for the second quarter of 2024. 
Via InvestorPlace
News headline image
CEL-SCI Announces Pricing of $5 Million Public Offering
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Proposed Public Offering of Common Stock
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study
From CEL-SCI Corporation
Via Business Wire
News headline image
U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025
From CEL-SCI Corporation
Via Business Wire
News headline image
FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress
From CEL-SCI Corporation
Via Business Wire
News headline image
The UK’s Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results
From CEL-SCI Corporation
Via Business Wire
BioMedNewsBreaks — CEL-SCI Corp. (NYSE American: CVM) Closes on $10.8M Best-Efforts Offering
Via Investor Brand Network
News headline image
CEL-SCI Announces Closing of $10.8 Million Offering
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Announces Pricing of $10.8 Million Offering
From CEL-SCI Corporation
Via Business Wire
News headline image
Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
 
Via Benzinga
News headline image
CEL-SCI’s Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Appoints Robert Watson as Chairperson of the Board
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population
From CEL-SCI Corporation
Via Business Wire
News headline image
Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor
From CEL-SCI Corporation
Via Business Wire
News headline image
CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results
From CEL-SCI Corporation
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why CEL-SCI (CVM) Shares Are Trading Higher ↗
CEL-SCI shares are trading higher by 18.6% during Wednesday's session. The company received positive feedback from the FDA regarding their cancer immunotherapy. 
Via Benzinga
News headline image
CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer
From CEL-SCI Corporation
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
CEL-SCI Appoints Mario Gobbo to Its Board of Directors
From CEL-SCI Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
>